Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
European Urology|January 13, 2021
Actinium-225 Prostate-specific Membrane Antigen Theranostics: Will α Beat β?Nattakorn Dhiantravan, Michael S Hofman, Aravind S Ravi Kumar
Clinical Nuclear Medicine|July 27, 2019
Concomitant Prostate Carcinoma and Follicular Lymphoma: "Flip-Flop" Appearances on PSMA and FDG PET/CT ScansNattakorn Dhiantravan, Elizabeth Hovey, Annmarie Bosco, et al.
Journal of Medical Imaging and Radiation Oncology|October 26, 2020
A role of PSMA PET/CT in multimodality imaging approach in adenoid cystic carcinomaNattakorn Dhiantravan, Aravind S Ravi Kumar, Karda Cavanagh, et al.
Future Oncology (London, England)|March 16, 2021
Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancerDominic Bagguley, Sean Ong, James P Buteau, et al.
EJNMMI Research|July 24, 2025
A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancerMatthew J Roberts, Natasha A Roberts, Anita Pelecanos, et al.
BJU International|March 8, 2021
UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol)Nattakorn Dhiantravan, Louise Emmett, Anthony M Joshua, et al.
European Urology Focus|November 11, 2020
Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to ProstatectomyNattakorn Dhiantravan, John Violet, Renu Eapen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 17, 2023
Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma managementShivanshan Pathmanathan, Arsalan Tariq, Adam Pearce, et al.
The Lancet. Oncology|September 18, 2024
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 studyArun A Azad, Mathias Bressel, Hsiang Tan, et al.
European Urology|October 27, 2023
Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 StudyRenu S Eapen, James P Buteau, Price Jackson, et al.
Pageof 2